Global Biopsy Devices Market Companies Analysis: Innovations, Competition & the Future of Diagnostic Precision

The global biopsy devices market is entering a transformative period, driven by rapid medical innovation, the rising burden of cancer worldwide, and growing demand for early and minimally invasive diagnostics. According to Renub Research, the market — valued at US$ 2.43 billion in 2024 — is projected to reach US$ 4.02 billion by 2033, expanding at a CAGR of 5.75% between 2025 and 2033.

This momentum is powered by several converging forces: the need for personalized treatment, the emphasis on early cancer detection, and the industry’s push toward less invasive, patient-friendly procedures. As healthcare providers shift toward optimized diagnostic workflows, biopsy tools — from fine-needle aspiration devices to advanced surgical biopsy systems — are becoming indispensable across radiology, oncology, gastroenterology, gynecology, and dermatology.

With demand rising, leading medical device companies are heavily investing in innovation, product diversification, AI integration, and sustainability initiatives. This article analyzes the key companies shaping the global biopsy devices market while evaluating their strategies, product launches, and competitive strengths.

Request Free Sample Report

The Rising Role of Biopsy Devices in Modern Diagnostics

Biopsy devices play a central role in the detection, staging, and monitoring of diseases, particularly cancer — now responsible for nearly 10 million deaths annually. These devices range from needle-based tools (fine-needle aspiration and core biopsy), to punch biopsy tools, to surgical biopsy instruments required for deep or complex tissue extraction.

The modern diagnostics ecosystem favors devices that are:

Minimally invasive

Capable of obtaining higher-volume samples

Compatible with imaging modalities (ultrasound, CT, endoscopy)

Designed for accuracy and patient comfort

Technological advancements — including sharper Franseen-tip needles, spring-coiled sheaths, AI-powered guidance systems, and single-use biopsy tools — are changing how physicians approach tissue sampling. These innovations reduce complications, improve sample integrity, and support quicker, more precise diagnosis.

Leading Companies Shaping the Global Biopsy Devices Market

Below is a detailed analysis of key manufacturers driving innovation across the biopsy landscape.

Cardinal Health, Inc.

Founded: 1971

Headquarters: United States

Website: www.cardinalhealth.com/en.html

Cardinal Health is a global healthcare solutions provider with a strong portfolio in medical consumables and biopsy instruments. Its biopsy tools are designed for minimally invasive and precise sampling across radiology, dermatology, and oncological procedures. Cardinal’s broad distribution network and hospital partnerships strengthen its presence in the biopsy devices market.

Hologic Inc.

Foundation: 1985

Headquarters: United States

Website: www.hologic.com

A global leader in women’s health, Hologic provides advanced diagnostic products and surgical tools. Its portfolio includes:

Breast imaging-guided biopsy systems

GYN surgical instruments

Skeletal health solutions

Hologic’s strong worldwide sales network and specialization in breast cancer diagnostics place it at the forefront of image-guided biopsy solutions.

Danaher Corporation

Founded: 1984

Headquarters: United States

Website: www.danaher.com

Danaher is a multinational powerhouse operating across biotechnology, diagnostics, and life sciences. Its biopsy and diagnostic technologies include:

Mass spectrometry tools

Genomics and cell analysis equipment

Clinical diagnostic platforms

Danaher’s acquisition-driven growth strategy and strong R&D capabilities give it a competitive advantage in enabling precision diagnostics.

Becton, Dickinson and Company (BD)

Founded: 1897

Headquarters: United States

Website: https://www.bd.com

BD is one of the most influential names in medical technology, offering:

Core and fine-needle biopsy solutions

Molecular diagnostic tools

Surgical instruments

Pre-fillable drug delivery systems

Its broad global footprint — with facilities across 15+ countries — helps BD maintain a robust supply chain and presence in emerging markets.

Boston Scientific Corporation

Founded: 1979

Headquarters: United States

Website: www.bostonscientific.com/en-US/Home.html

Boston Scientific specializes in interventional medical technologies across:

Gastroenterology

Interventional radiology

Neurological surgery

Pulmonology

Urology

Many of its devices support biopsy and tissue sampling used during endoscopic and minimally invasive interventions.

Key Product Launches Transforming Biopsy Procedures

Innovation remains the heart of competition in the biopsy devices market. Notable recent product launches include:

Medtronic plc — AI-Powered ColonPRO (April 2024)

Medtronic introduced ColonPRO, an enhancement to its GI Genius™ AI-powered endoscopy solution. Designed to detect colorectal polyps with greater accuracy, ColonPRO:

Boosts diagnostic precision

Improves workflow efficiency

Enhances patient outcomes in colorectal cancer screening

This marks a critical step forward in integrating AI with biopsy and endoscopic procedures.

Olympus Corporation — SecureFlex Single-Use FNB Tool (October 2025)

Olympus launched SecureFlex, a single-use fine-needle biopsy tool designed for:

Ultrasound-guided GI tract biopsies

Improved diagnosis of pancreatic cancer

Enhanced sample acquisition with minimized contamination

SecureFlex will roll out across Europe and Japan first, followed by global distribution.

SWOT Analyses of Key Biopsy Innovators

Cook Medical — Precision & Engineering Excellence

Strength: Cook Medical stands out due to its continuous innovation, particularly with the EchoTip ClearCore EUS Biopsy Needle, offering:

Cobalt-chromium Franseen tip

Spring-coiled sheath for flexibility

Sharper puncture force

Superior tissue sample integrity

With 94% physician satisfaction during pre-launch testing, Cook’s solutions remain trusted for their accuracy and reliability.

INRAD, Inc. — “No-Throw” Biopsy Technology Leader

Strength: INRAD’s patented PreciseCore device incorporates No-Throw needle technology, eliminating forward stylet movement — a common limitation in traditional core biopsy tools. Advantages include:

Reduced risk of overshoot trauma

One-handed operation

Ultrasound compatibility

High sampling precision

This makes INRAD a preferred supplier for soft tissue biopsies requiring exceptional accuracy.

Recent Strategic Developments in the Global Market

CONMED Corporation — Acquisition of In2Bones Global Inc.

CONMED expanded its portfolio through the acquisition of In2Bones, funded using a mix of convertible notes, credit facility borrowings, and cash reserves. This acquisition enhances CONMED’s presence in orthopedic and biopsy-related devices.

Argon Medical Devices — Launch of SuperCore Advantage™ (May 2023)

Argon introduced the SuperCore Advantage™ Semi-Automatic Biopsy Instrument, offering:

Larger tissue sample volume

Enhanced diagnostic accuracy

Multiple gauge and length options

This strengthens Argon’s competitive positioning in soft tissue biopsy technologies.

Sustainability Commitments from Key Market Players

Sustainability is shaping procurement decisions as hospitals increasingly prioritize environmentally responsible suppliers.

Stryker Corporation — Carbon Neutrality by 2030

Stryker aims to:

Reduce Scope 1 & 2 emissions by 20% by 2024

Shift to 100% renewable electricity by 2027

Achieve full carbon neutrality by 2030

The company is adopting solar, wind, hydroelectric, and other renewable energy sources to meet its sustainability targets.

B. Braun Melsungen AG — 50% Emissions Cut by 2030

B. Braun plans to:

Reduce Scope 1 & 2 emissions by 50% by 2030

Implement energy-saving initiatives (25% savings at its Hanoi plant)

Roll out CO₂-neutral production through:

Photovoltaics

Heat pumps

Energy recovery systems

Ice-storage systems

The company increasingly integrates renewable energy into its manufacturing workflows.

Comprehensive Market Assessment Framework

The following components define the full competitive evaluation of the global biopsy devices industry:

1. Historical Trends

Growth patterns, technological evolution, regulatory milestones.

2. Forecast Analysis

Demand across hospitals, ambulatory surgical centers, diagnostic laboratories.

3. Market Share Analysis

Comparison of company strengths, regional reach, and product diversification.

4. Company-by-Company Deep Dive

For each firm (Cardinal, Hologic, Danaher, BD, Boston Scientific, Medtronic, Olympus, CONMED, Argon, Cook Medical, INRAD, Fujifilm, Stryker, Merit Medical, B. Braun):

Overview

History & Mission

Business Strategy

Workforce Insights

Key Leadership

R&D and Product Pipeline

M&A and Partnerships

Sustainability Initiatives

SWOT Analysis

Revenue & Market Position

This systematic framework enables stakeholders to evaluate how each company contributes to — and competes within — the global biopsy devices landscape.

Final Thoughts: A Future Built on Precision, Innovation & Patient-Centered Diagnostics

The global biopsy devices market is on a powerful upward trajectory. Innovations such as AI-enabled biopsy guidance, single-use devices, improved tissue sampling geometry, and minimally invasive tools are redefining what is possible in diagnostic medicine.

As cancer prevalence rises and the push for early detection intensifies, biopsy devices will play a critical role in shaping the future of personalized treatment and value-based healthcare. Companies investing in R&D, sustainability, and digitally enhanced diagnostics will lead the next decade of transformation.

With a projected market value of US$ 4.02 billion by 2033, the opportunity for growth is immense — and the companies highlighted in this analysis are setting the benchmark for precision, patient comfort, and clinical excellence.